Clearmind Medicine Inc. (NASDAQ: CMND) announced the publication of an international patent application for a combination therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease. The patent was filed under the Patent Cooperation Treaty.

The therapy combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), developed through collaboration with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (NASDAQ: SPRC).

The treatment is designed as a non-hallucinogenic neuroplastogen therapy for obesity, which affects over 890 million adults worldwide, and MASLD, impacting approximately 30% of the global adult population according to the company.

"The publication of this international patent is part of our mission to develop innovative, proprietary and transformative therapies for underserved metabolic and neurological conditions," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

The company stated the global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035.

Clearmind Medicine is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics. The company's intellectual portfolio consists of 19 patent families, including 31 granted patents.

The information is based on a press release statement from the company.